Related Articles
Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer
Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens
Availability of irinotecan in a second-line setting confers survival benefit to patients with advanced gastric cancer refractory to fluoropyrimidine-based regimens
Phase II study on the combination of irinotecan plus cisplatin as a second‑line therapy in patients with advanced or recurrent gastric cancer
Chemotherapy for urothelial carcinoma in renal transplantation patients: Initial results from a single center